Home/Publication/LAV, ARCH Venture Continue to Back Neurodegenerative Treatments
LAV, ARCH Venture Continue to Back Neurodegenerative Treatments 

12 Dec 2025

US$ 20.00

Lilly Asia Ventures and ARCH Venture Partners have co-led the US$53 m equity financing round of the US-based SciNeuro...

Price / article: US$20.00
OR existing subscriber
Related Publications

Subscribers’ Weekly for the week ending 19 December 2025...

IPOs of Moore Treads and MetaX are powerful signals that China’s AI chip industry is not far from being self-sufficient...

Connect With Us

We love to share Asia PE insights and news from time to time. Drop us your email address if you like to hear from us.

Rest assured that your email address will not be shared, as we hate spams as much as you do.